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A bstract  Acute renal failure is one of the hallmarks of the closely related glycolipid, which is similar to a glycolipid
hemolytic uremic syndrome (HUS). Infection with a verocy- involved in the VT-dependent cytokine production in mono-
totoxin (VT)- or Shiga-like toxin (SLT)-producing Escherichia cytes. VT did not induce the release of cytokines or chemo-
co li  has been strongly implicated in the etiology of the epi- kines in mesangial cells. In VT-susceptible cells, binding of
demie form of HUS. The functional receptor for these closely VT to Gb3 causes cell death by the inhibition of protein
related toxins appears to be a glycosphingolipid, globotriao- synthesis. Although protein synthesis was inhibited in mesan-
sylceramide (Gb3). Endothelial damage in the glomeruli and gial cells, all cells remained viable, both under basal and tumor
arterioles of the kidney induced by VT is believed to play a necrosis factor-a-stimulated conditions. However, the marked
crucial role in the pathogenesis of HUS. However, little infor- reduction in protein synthesis may impair a proper response of
mation is available regarding the effects of VT on mesangial the cells in conditions of increased demand of newly synthe-
cells, which also play an important role in glomerular function, sized proteins. Furthermore, VT markedly inhibited DNA syn-
In this study, the effects of VT on human mesangial cells in thesis and proliferation of mesangial cells, The inhibition of
vitro  were investigated. Mesangial cells were enriched by mitogenesis was also found with the B-subunit of VT-1 alone,
collecting hillock-shaped outgrowths derived from adult hu- albeit to a lesser extent, without a significant effect on protein
man glomeruli and subsequently purified by elimination of synthesis. Because the inhibition of protein synthesis involves
contaminating epithelial cells by immunoseparation with ulex the A-subunit, this suggests that two distinct mechanisms con-
europaeus lectin-I (UEA-I)-coated dynabeads. The obtained tribute to the effects of VT on protein synthesis and mitogen-
and subcultured mesangial cell populations were >98% pure. esis. Intracellular routing of VT (A- and B-subunits) may vary
Their mesangial nature was established by the presence of between cell types and result in differential effects on human
a-smooth muscle cell actin in highly confluent cultures and the mesangial cells when compared with other cell types. (J Am
absence of cytokeratin or platelet/endothelial cell adhesion Soc Nephrol 8: 1877-1888, 1997) 
m olecule-1. Mesangial cells bound VT to bands of Gb3 and a
Hemolytic uremic syndrome (HUS) is a clinical syndrome 
characterized by the triad hemolytic anemia, thrombocytope­
nia, and acute renal failure (1). Infection with a verocytotoxin 
(VT)-producing Escherichia coli is strongly implicated in the 
etiology of the epidemic form of HUS (2). Endothelial cell
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damage of glomeruli and kidney arterioles by interaction of VT 
with its receptor, resulting in a consecutive cascade of mutually 
influencing factors, plays an important role in the pathogenesis 
of HUS (3). Renal histopathological studies of HUS patients 
reveal swollen and detached endothelial cells and deposits of 
fibrin, all within the glomerulus (4). Pathological findings in 
the mesangial area of HUS patients are scarcely documented, 
reporting signs of mesangial disintegration associated with 
reparative changes varying both in severity and distribution. 
Mesangial hypercellularity is not a common feature of this 
syndrome (4-8). The intervening basement membrane is lack­
ing at the point where the mesangium comes in closest contact 
with glomerular circulation (9) and, thus, only a single layer of
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damaged, fenestrated endothelium is separating glomerular 
circulation from the mesangium in HUS patients. Therefore, 
we hypothesized that VT and other plasma constituents may 
easily enter this space and accumulate in the matrix or may be
taken up by endocytosis. Under normal circumstances, mesan- Primary Culture and Purification
growth factor (prepared form bovine brains as described by Maciag 
[20]) and plated on gelatin (1% Fluka BioChemika, Buchs, Switzer- 
land)-coated wells (Costar, Cambridge, MA).
gial cells play a pivotal role in the regulation of glomerular 
hemodynamics and structural support of the glomerular tuft by 
their capacities to contract and to produce extracellular matrix 
components, respectively. Besides, these cells have phagocytic 
properties and are able to generate a variety of vasoactive 
agents, such as growth factors, cytokines, prostaglandins, and 
oxygen radicals, which may attract and activate inflammatory 
cells in a paracrine manner and exert autocrine effects on 
mesangial cells themselves. In addition, mesangial cells not 
only produce a variety of factors involved in the regulation of 
cell proliferation, but also are target sites for the regulation of 
cell proliferation (reviewed in references 10 through 16), The 
interaction of VT with mesangial cells may very well interfere 
with normal mesangial functions and in that way affect renal 
function. In this study, the effects of VT on pure populations of 
human mesangial cells in culture, which were free of contam­
inating endothelial and epithelial cells, were investigated, Al­
though human mesangial cells do possess a glycolipid receptor 
for VT, the toxin did not appear to affect the number of viable 
adherent human mesangial cells significantly. In contrast to 
human monocytes, in which VT induced cytokine release and 
also did not affect cell viability, human mesangial cells were 
not induced by VT to release cytokines. On the contrary, VT 
markedly inhibited DNA and, to a lesser extent, overall protein 
synthesis. Two distinct mechanisms appeared to be involved in 
these inhibitory effects. One was associated with the A-sub- 
unit, known to inhibit eukaryotic protein synthesis in other cell 
types (17,18), and the second mechanism was linked to the 
B-subunit of VT, which is normally required for the binding of 
the holotoxin to its functional receptor (19).
Materials and Methods
Isolation o f  Glomeruli
Studies were performed with human kidney tissue obtained from 
kidneys that had been surgically excised because of the presence of a 
localized neoplasia (donor age range, 45 to 70 yr). Written consent 
was obtained from the Medical Ethical Review Board of the Univer­
sity Hospital (Nijmegen, The Netherlands). Macroscopically normal 
portions of cortex, located at some distance (1 to 2 cm) from the 
neoplastic process, were dissected under sterile conditions. Glomeruli 
were subsequently isolated by a gradual sieving procedure and col­
lected on top of sieves with openings sizes of ISO, 125, 108, or 90 jam 
(Endecotts, London, England). Resulting pure populations of glomer­
uli were mildly treated with 0.1% (wt/vol) collagenase type 2 CLS 
(Worthington Biochemical, Freehold, NJ) for 30 min at 37°C. After 
collagenase treatment, the glomeruli were washed, centrifuged, and 
resuspended in complete media, which consisted of M l99 (BioWhit- 
taker, Walkersville, MD) supplemented with 10% (vol/vol) newborn 
calf serum (NBCS; GIBCO, Grand Island, NY), 10% (vol/vol) human 
serum (HS; procured from a local blood bank), 2 mmol/L glutamine 
(ICN Biomedical, Costa Mesa, CA), 100 IU/ml penicillin, 0.1 mg/ml 
streptomycin, 5 U/ml heparin (Leo Pharmaceuticals, Weesp, The 
Netherlands), and 150 mg/L of a crude preparation of endothelial cell
In general, the glomeruli attached within a few days, after which 
outgrowth of predominantly epithelial and limited numbers of endo­
thelial cells was noted. Epithelial cells displayed their typical polyg­
onal, cobblestone morphology, whereas glomerular micro vascular 
endothelial cells exhibited a slightly elongated morphology, with a 
nucleus containing one or two nucleoli and a dark perinuclear cyto­
plasm area surrounded by a bright halo. These endothelial cells, unless 
selectively collected, were rapidly overgrown by epithelial cells dur­
ing the first days of culture. Within 10 to 30 d after the glomeruli were 
seeded, outgrowth of mesangial cells was noticed (Figure 1A), ini­
tially showing the characteristic spindle/stellate-shaped morphology 
and, later, the well recognized elongated conformation. These elon­
gated cells exhibited a typical growth pattern of overcrossing hillock- 
forming cells (21); we selectively collected them by scraping them off 
the tissue culture plate (22), using the tip of a plastic pipette, and 
explanted them onto gelatin-coated six-well plates (Figure IB), 
Whereas confluent populations of these mesangial cells were free of 
contaminating endothelial cells, the presence of small numbers of 
epithelial cells was not negligible (5 to 15%), as demonstrated by 
immunofluorescence studies, using monoclonal antibodies against 
endothelial (anti-platelet/endothelial cell adhesion molecule-1 [PE- 
CAM-1]) and epithelial cells (anti-cytokeratin 8), respectively. To 
further purify the mesangial cell populations, epithelial cells were 
eliminated by an immunomagnetic separation technique, using ulex 
europaeus lectin-1 (UEA-I) (Sigma, St. Louis, MO)-coated Dynabeads 
(M-450 tosyl-activated Dynabeads; Dynal, Oslo, Norway) that 
showed affinity for epithelial cells but not for mesangial cells, Similar 
results were obtained when a fluorescence-activated cell sorter anal­
ysis was performed using tetramethylrhodamine isothiocyanate-la- 
beled UEA-I (Sigma), which consistently showed a much higher 
binding to epithelial cells than to mesangial cells. The immunomag­
netic separation technique was performed by incubating trypsinized 
and subsequently washed cells with UEA-I-coated Dynabeads for 30 
min at room temperature with occasional agitation. Epithelial cells 
that bound to the beads were collected with a magnetic particle 
concentrator, and the mesangial cells present in the supernatant were 
pooled and exposed to a second immunomagnetic separation tech­
nique to remove the last contaminating epithelial cells. UEA-I-nega- 
tive mesangial cells were plated onto gelatin-coated wells and grown 
in a humidified atmosphere of 95% air and 5% C 0 2. Resulting cell 
populations were highly purified populations of human mesangial 
cells (Figure 1C). Subculturing of these cells with a split ratio of 1:3 
to 1:6 was successfully performed to at least 10 passages without 
observable changes in morphology and function.
Characterization o f  Human Mesangial Cells
Primary and serially passaged cultures were characterized using the 
following criteria:
1. Morphological criteria: Primary outgrowing mesangial cells re­
sembled subcultured mesangial cells as assessed by phase-contrast 
microscopy; they initially displayed their characteristic spindle/ 
stellate-shaped morphology and later showed the well recognized 
elongated form. Confluent and highly confluent cultures exhibited 
a typical growth pattern of overcrossing cells (Figure I, B and C). 
Neither contaminating polygonal epithelial cells nor contaminating
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1, Phase-contrast microscopy of primary culture of human 
m esangial cells. Human glomeruli were isolated by a gradual sieving 
procedure and mildly treated with collagenase. The glomeruli and 
glom erular remnants were then plated on gelatin-coated plates. After 
attachment, outgrowth of primarily endothelial and epithelial cells 
w a s  observed. Within 10 to 30 d after the glomeruli were seeded, 
outgrow th of mesangial cells was noticed, showing their characteristic 
spindle/stellate-shaped morphology and, later, the well recognized 
elongated conformation (A); the elongated cells exhibited a typical 
g row th  pattern of overcrossing hillock-forming cells. Mesangial cell 
populations were enriched by collecting these hillock-forming cells 
(B ). Contaminating epithelial cells were eliminated by performing an 
immunomagnetic separation technique, using ulex europaeus lectin 
I-coated Dynabeads, resulting in pure populations of human mesan­
g ia l cells (C). Magnification, X75.
glomerular endothelial cells were observed in purified populations 
of mesangial cells by phase-contrast microscopy.
Immunological criteria: Indirect immunofluorescence studies of 
outgrowing as well as subcultured mesangial cells revealed intense 
staining of intracellular filaments with anti-a smooth muscle actin 
(Sigma; clone 1A.4; 1:300; Figure 2A). However, whereas immu- 
noreactivity with a-smooth muscle actin in primary cultured mes­
angial cells did not seem to depend on the cell density, immuno- 
reactivity with a-smooth muscle actin in subcultured mesangial 
cells was predominantly observed when the cells were highly 
confluent. No differences were noticed when comparing F-actin
Figure 2. Indirect immunofluorescence studies of human mesangial 
cells (A), glomerular microvascular endothelial cells (B), and human 
renal epithelial cells (C) with antibodies against (respectively) a - 
smooth muscle actin, platelet/endothelial cell adhesion molecule-1 
antigen, and cytokeratin 8. Magnification, X350.
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filaments (phalloidin-tetramethylrhodarmne isothiocyanate; 
Sigma) of primary and subcultured mesangial cells at any cell 
density. The cultured mesangial cells showed no reactivity to the 
anti-PEC AM-1 antibody (23) or to the anti-cytokeratin 8 antibody 
(24), excluding (respectively) contaminating endothelial and epi­
thelial cells (data not shown). Glomerular microvascular endothe­
lial cells did react with anti-PEC AM-1 antibody (Figure 2B), 
whereas renal epithelial cells did with anti-cytokeratin 8 antibody 
(Figure 2C).
3. Functional criteria: Brown et a l  (25) reported the synthesis of 
urokinase by human epithelial cells but not by human mesangial 
cells. Therefore, we measured urokinase-type plasminogen activa­
tor (u-PA) antigen in conditioned medium by a sandwich enzyme- 
linked immunosorbent assay (ELISA) previously described by van 
Hinsbergh et al. (26),
Cytotoxicity Assay
Mesangial cells were cultured in complete medium on gelatin - 
coated 24-well plates and grown until confluence. Subsequently, the 
cells were preincubated with or without tumor necrosis factor-a 
(TNFa, 10 ng/ml; Boehringer Mannheim, Mannheim, Germany) for 
24 h. The next day, the medium was aspirated, and the cells were 
washed once. New medium, consisting of 20% fetal calf serum 
instead of 10% NBCS and 10% HS because of the potential neutral­
izing activity of NBCS and HS against VT, was added with different 
concentrations of VT-1. After 4 to 72 h, the cells were washed with 
phosphate-buffered saline (PBS) and adherent cells were released 
with trypsin/ethylenediaminetetra-acetate (EDTA; 0*5 g trypsin 1:250/ 
0.2 g EDTA in 1 L of Modified Puck’s Saline A; GIBCO). Trypan 
blue was added, and viable, trypan blue-excluding cells were counted 
in a hemocytometer. To study the influence of cell density, cells at 
different degrees of cell density were preincubated with and without 
TNFa and tested for VT-1 (27), VT-2 (28) (kindly provided by Dr. 
M. A. Karmali), and VT-I B-subunit (29) (kindly provided by Dr. 
J. L. Brunton, The Hospital for Sick Children, Toronto, Ontario, 
Canada) cytotoxicity as described above.
Iodination o f  VT-1 and the Binding o f  125I~VT-1 to 
Human Mesangial Cells
VT-1 was radiolabeled with Na-125I according to the iodogen 
procedure (30). The radioactive activity of 125I-VT-1 ranged from 10 
to 12 ¡jbCUfig protein. Mesangial cells were grown in 24-well plates 
until they reached confluence. The cells were then preincubated with 
TNFa for 24 h at 37°C, after which the cells were washed with 
Ml 99/0.1% human serum albumin (pyrogen-free HSA; Central Lab­
oratory of the Red Cross Blood Transfusion Service, Amsterdam, The 
Netherlands) and incubated for 3 h with 0.25 to 16 nmol/L 125I-VT-1 
in M199/0.1% HSA at 0°C. After 3 h, the incubation medium was 
aspirated, and the cells were washed five times in M l99 medium/ 
0.1% HSA. Cell-associated 125I-VT-l was determined by solubilizing 
the cells in 400 ¡A of 1 mol/L sodium hydroxide at room temperature 
and counting radioactivity in a gamma counter. Nonspecific binding 
was assessed in parallel incubation by determining i25I-VT-l binding 
in the presence of a 100-fold excess of unlabeled VT-1. Cellular 
specific binding was calculated by subtracting the nonspecific binding 
from the cellular binding of 12SI-VT-1, as determined in the absence 
of unlabeled VT-1. All determinations were done in duplicate. Data 
were analyzed using the method described by Scatchard (31).
Glycolipid Extraction and Thin-Layer Chromatography
Confluent monolayers of mesangial cells were cultured in six-well 
plates for 24 h with and without TNFa. Subsequently, the cells were
washed with PBS and trypsinized, after which neutral glycolipids 
were extracted and separated by methods described earlier by Ling- 
wood et a l.(32). After thin-layer chromatography (TLC), the silica gel 
TLC plate was soaked three times for 1 min in 0.01% polyisobutyl- 
methacrylate (Polysciences, Warrington, PA) in hexane and air-dried, 
followed by overnight incubation in PBS/1 % bovine serum albumin 
(BSA; Sigma) and 0.05% Tween 20. The plate was subsequently 
incubated with 50 ml of 1.5 nmol/L 125I-VT-1 in 1% BSA and 0.05% 
Tween 20 in PBS for 4 h at 4°C. The plate was washed extensively 
with PBS supplemented with 1% BSA and 0.05% Tween 20, air- 
dried, and then analyzed by a Fuji BAS 1000 Phosphorlmager (Lei­
den, The Netherlands).
Cytokine Production
Human mesangial cells were grown to confluence in 24-well plates 
and subsequently exposed to either lipopolysaccharide (LPS; Esche­
richia coli, serotype 055:B5, Sigma), TNFa, VT-1, VT-2, or B- 
subunit during a 24-h incubation period. Control cells were exposed to 
medium alone. After the indicated period of time, the supernatants 
were procured and centrifugated and stored at — 20°C until they were 
assayed for the presence of cytokines. TNFa and interleukin 1-|3 
(ILrljS) were determined by RIA as described previously (33). The 
sensitivity of both assays was 80 ng/ml, 1L-6 was measured by ELISA 
as previously described by Van Setten et al. (33). The sensitivity of 
this ELISA was 20 pg/ml. IL-8 and monocyte chemoattractant pro­
tein-1 (MCP-1) were also determined by ELISA, In brief, ELISA
plates (Merlin Diagnostic Systems, Rotterdam, The Netherlands) were
i
coated overnight with (respectively) 0.5 /mg/ml ÏL-8 monoclonal an­
tibody and 3 jug/ml MCP-1 monoclonal antibody (R&D systems, 
Abingdon, Oxon, UK) in coating buffer. The next day, plates were 
washed three times with 0.5% (vol/vol) Tween/PBS, after which the 
plates were blocked for 1.5 h with 5% BSA in PBS. After being 
blocked, the plates were washed three times, and 50 /xl of sample and 
standard (25 to 2500 pg/ml and 0.25 to 25 ng/ml, respectively) were 
added and incubated for 1 h at 37°C. Subsequently, the plates were 
washed, and biotinylated secondary antibodies (respectively, 3 ml 
and 4 /Ltg/ml; R&D Systems) were added for 45 min at 37°C. Plates 
were washed five times and incubated with streptavidin peroxidase 
(0.5 /xg/ml) for 30 min at 37°C, after which the plates were washed 
again five times and exposed to o-phenylenediamine dihydrochloride 
(Sigma) for 30 min. The reaction was stopped by the addition of 2 
mol/L H2S 04 (50 /xl/well). Absorbency was read at 492 nm on a 
Titertek Multiscan. Preliminary experiments showed that a 1:10 to 
100 dilution of the culture supernatants was needed to ensure that the 
results fell on the linear portion of the standard curve. The recovery 
rate was >95%, and parallelism was demonstrated for different dilu­
tions. The sensitivities of the IL-8 and MCP-1 ELISA were 50 pg/ml 
and 0.25 ng/ml, respectively. All samples and standards were assayed 
in duplicate.
Cell Proliferation and Protein Synthesis
Cell proliferation and protein synthesis were determined by assay­
ing the incorporation of 3H-thymidine and 35S-methionine into newly 
synthesized DNA and proteins, respectively. Mesangial cells were 
cultured in 24-well plates and grown until confluence. Subsequently, 
the cells were preincubated with or without TNFa for 24 h. The next 
day, the cells were washed and incubated with VT-1, VT-2, and 
B-subunit in medium containing 3H-thymidine (1 ¡jlCi/ml complete 
medium) and 35S-methionine (0,25 jtxCi/ml complete medium) during 
a 4- to 48-h incubation period. After incubation, the supernatant was 
aspirated, and the cells were washed with PBS and precipitated with
Effects of Verocy totoxin on Human Mesangial Cells 1881
10 and 5% TCA, respectively. After solubilizing in 0.3 ml of 0.3 
mol/L NaOH, the contents of each well were neutralized with HCl (60 
/¿Ï o f  15  mol/L) and counted in a liquid scintillation counter.
Results
Iso la tion  and Characterization o f  Pure Cultures o f  
H u m a n  Mesangial Cells
Primary outgrowths from glomeruli that were mildly treated 
w ith collagenase consisted of mostly epithelial and mesangial 
ce lls , the latter forming “hillocks.” Mesangial cell populations 
w ere enriched by collecting “hillock”-forming cells and further 
purified by selective elimination of contaminating epithelial 
c e lls  by an immunomagnetic separation technique, using UEA- 
I-coated dynabeads. The cells were identified as mesangial 
c e lls  because of their characteristic morphology by phase- 
contrast microscopy and on the basis of immunofluorescence 
studies. By phase-contrast microscopy, the mesangial cells 
in itially showed their typical spindle/s tel late-shaped morphol­
o g y , followed by their characteristic growth pattern of over­
crossing cells when reaching confluence (Figure 1). Immuno­
fluorescence studies revealed intense staining of intracellular 
filam ents with a-smooth muscle actin (Figure 2A), whereas no 
im m unoreactivity was noticed with PECAM-1- and cytokera- 
tin antibodies. In addition, epithelial cell contamination was 
m ad e unlikely by the finding that the u-PA antigen concentra­
tio n  in conditioned media of cultured mesangial cells was 
present in very low quantities (<0.4 ng/24 h per 105 cells; 
three different cultures), whereas the presence of u-PA antigen 
in conditioned media of cultured renal epithelial cells was 
abundant (>500 ng/24 h per 105 cells; three different cultures).
E f f e c t  o f  VT-1 on the Number o f  Viable Human 
M e s a n g ia l  Cells
T o  evaluate whether confluent human mesangial cells are 
sensitive to the toxic effect of VT-1, cells were exposed to 
various concentrations of VT-1 (1 pmol/L to 10 nmol/L) for 4 
to  7 2  h, after which the number of viable adherent cells was 
assessed. After 24 h of exposure to VT-1 (Table 1), only a 
s lig h t decrease in the number of viable adherent mesangial 
c e l ls  was observed. No further decrease in the number of viable
T a b le  1. Effect of VT-1 on the number of viable adherent
human mesangial cellsa
Number of Viable Adherent Cells
Concentration (% of control)
t =: 4 h t = 12 h t = 24 h
VT-1 (1 pmol/L) 111 *+■7 102 3.5 102 Hh 14
VT-1 (10 pmol/L) 99 ± 11 100 -H 13 90 6
VT-1 (100 pmol/L) 99 8 103 4 87 4
VT-1 (1 nmol/L) 101 7 106 6 86 4
V T -1(10 nmol/L) 106 ± 9 109 9 88 12
a Values are mean ±  SD of three different experiments with 
th re e  different populations of human mesangial cells. t> time.
adherent cells was observed after VT-1 exposure of the mes­
angial cells for 48 to 72 h (data not shown).
Previous observations in human umbilical vein endothelial 
cells (3) and glomerular micro vascular endothelial cells (34) 
have shown that VT cytotoxicity depends on the additional 
stimulation with the inflammatory mediator TNFa and the 
degree of cell density, subconfluent cells showing the highest 
sensitivity. However, in human mesangial cell populations of 
two different donors, we did not observe significant increases 
in susceptibility upon preincubation with TNFa or when the 
degree of cell density was varied (data not shown).
VT-1 Binding to Mesangial Cells and the Effect o f  
TNFa on the Number o f  VT-1 Receptors
Because no significant cytotoxic effects were observed, we 
wondered whether human mesangial cells, like other eukary­
otic cells, do bind VT to their cell membrane. Therefore, 
binding experiments with 125I-VT-1 were performed. Binding 
of 125I-VT-1 to human mesangial cells was saturable (Figure 
3A) and specific; 125I-VT-1 binding was entirely (95%) dis­
placed by a 100-fold excess of unlabeled VT-1, Pretreatment of 
mesangial cells with TNFa: resulted in an increase in l25I-VT-l 
binding (Figure 3A). Scatchard plot analysis revealed that one 
type of binding site is involved in VT-1 binding to human 
mesangial cells (Figure 3B). In addition, Scatchard plot anal­
ysis showed that 24-h preincubation of confluent human mes­
angial cells with TNFa caused a twofold increase in the num­
ber of specific binding sites, whereas the apparent affinity of 
VT-1 did not change significantly.
Receptor Analysis by Thin-Layer Chromatography
To evaluate whether human mesangial cells bind VT-1 to the 
cell surface via a glycolipid (like other eukaryotic cells), neu­
tral glycolipid extracts from both unstimulated human mesan­
gial cells, as well as TNFasstimnlated human mesangial cells, 
were prepared. Neutral glycolipids were separated by TLC, 
after which the chromatograms were incubated with 125I-VT-1. 
After extensive washing, the bound 125I-VT-1 was detected by 
exposure to a phosphorlmager. The radiolabeled VT-1 bound 
strongly to Gb3 and not to Gb4 when a standard preparation of 
neutral glycolipids was tested (Figure 4, lane E). In unstimu­
lated and TNFa-stimulated human mesangial cells, binding of 
1251-VT-1 occurred to three different bands (Figure 4, lane A 
and B). The upper two bands most likely represent Gb3 with 
different fatty acyl moieties (35,36). The third band, running 
slightly ahead of Gb4, has been observed previously in human 
monocytes, in which VT-1 induced cytokine release (33). The 
exact nature of this receptor has not yet been elucidated. The 
increase in 125I-VT-1 binding to the glycolipid extracts of 
TNFa-stimulated human mesangial cells indicates that the 
synthesis of VT-1 receptors is increased rather than only a 
reflection of a redistribution of VT-1 receptors from intracel­
lular stores toward the plasma membrane. This pattern was 
consistently found with different preparations of human mes­
angial cells obtained from two different donors.
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Figure 3. Tumor necrosis factor a. (TNFa) increases the specific 
binding of I25I-VT~1 to human mesangial cells. (A) Human mesangial 
cells of one representative donor were grown to confluence and 
pretreated with either control medium (open squares) or TNFa (10 
ng/ml; filled squares) for 24 h. The cells were then incubated with
J2SI-VT~1 (0.25 to 16 nmol/L) for 3 h at 
4°C, after which specific binding of i25I-VT-l to mesangial cells was 
calculated as indicated in Materials and Methods. (B) Scatchard plot 
analysis of 125I-VT-1 binding to human mesangial cells preincubated 
with either control medium (open circles) or TNFa (10 ng/ml; filled 
circles) for 24 h.
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Figure 4. 125I-VT-1 binding to glycolipids extracted from purified 
populations of human mesangial cells. Glycolipids were extracted 
from confluent human mesangial cells, separated by thin-layer chro­
matography, assayed for l25I~VT-l binding, and visualized by a 
phosphorimager. Lanes A and B, Glycolipid extracts of 60 cm2 human 
mesangial cells of one representative donor. Lane A, Control mesan­
gial cells. Lane B, TNFa-treated (10 ng/ml) mesangial cells. Lane C, 
Glycolipid extracts of 10 X 106 lipopolysaccharide-pretreated human 
monocytes. Lane D, Glycolipid extract of 75 cm2 TNFa-pretreated 
human umbilical vein endothelial cells. Lane E, Standard neutral 
glycolipids: 2 fig of each glycolipid. G bl, gal ac tos y 1 c er ami de ; Gb2, 
lactosylceramide; Gb3, globotriaosylceramide; Gb4, globotetraosyl- 
ceramide.
MCP-1, as was determined by sandwich ELISA, whereas 
TNFa and particularly IL-lß levels were not detectable by 
sensitive RIA. Upon stimulation with TNFa: (10 ng/ml) for 
24 h, the concentration of IL-6 , IL-8, and MCP-1 increased to 
15 ng/ml, 185 ng/ml, and 122.5 ng/ml, respectively (mean of 
two different donors). In addition, LPS induced the mesangial 
cells to release IL-6 , IL-8 , and MCP-1 (Table 2). Neither 
Effect o f  VT on the Production o f  Cytokines by Human TNFa nor LPS induced the secretion of either IL-lß or TNFa
Mesangial Cells (Table 2). Exposure of the two different donors’ human mes-
Because mesangial cells possess a VT-1 receptor similar to angial cells to VT-1 (0.1 pmol/L to 10 nmol/L), VT-2 (0.1
that of monocytes, which is believed to mediate VT-1-depen- pmol/L to 10 nmol/L), or the B-subunit (1 jug/ml) alone did not
dent cytokine induction (33), we studied whether VT also enhance the production of the measured cytokines significantly
induces cytokine release in human mesangial cells. When (Table 2). Similar results were obtained with the human mes-
conditioned media of two different populations of human mes- angial cells of a third donor, although the mean values of all
angial cells were assayed for the presence of IL-6 , IL-8 , five measured cytokines of this donor were lower, probably
MCP-1, IL-lß, and TNFa, we observed that mesangial cells indicating individual differences in the capacity to secrete
constitutively release only small amounts of IL-6 , IL-8, and inflammatory mediators upon various stimuli.
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Table 2. Effect of VT on the production of cytokines and chemokines by human mesangial cells1
VT IL-lß(ng/ml)
TNFa
(ng/ml)
IL-6
(ng/ml)
IL-8
(ng/ml)
MCP-1 
(ng/ml)
Control <0.08 0.19 ± 0.02 1.0 ±  0.1 2.4 ±  0.8 26.0 ±  0.0
LPS (1 jLtg/ml) <0.08 0.12 ±  0.01 36.9 ±  5.1 136.0 ±  38 91.5 ±  0.7
TNFa (10 ng/ml) <0.08 5.64 ±  2.34 15.0 ± 0.8 185.0 ±  15.6 122.5 ± 24.7
VT-1 (10 nmol/L) <0.08 0.18 ±  0.04 1.0 ±  0.02 1.4 ±  0.3 20.4 ± 0.8
VT-2 (10 nmol/L) <0.08 0.18 ±  0.01 1.0 ± 0 .3 2.7 ± 0 .1 24.1 ±  1.6
B-subunit (1 /xg/ml) <0.08 0.16 ±  0.03 1.0 ±  0.1 2.7 ±  0.3 25.1 ±  2.8
a Values are the mean (ng/ml) ±  SD of two mnerent experiments witn t\ 
factor-a; MCP, monocyte che mo attrae tant protein; LPS, lipopolysacch aride.
Effect o f  VT-1 and VT-2 on Cell Proliferation and  
Prote in  Synthesis
When mesangial cells were incubated with either control 
medium alone or control medium supplemented with VT-1, we 
observed that the number of cells increased under control 
conditions but not after exposure to VT. Therefore, we evalu­
ated the effect of VT on cell proliferation and overall protein 
synthesis by measuring 3H-thymidine incorporation in DNA 
and ‘ S-methionine incorporation in newly synthesized pro­
teins.
Figure 5, panels A and B, show the time- and concentration- 
dependent inhibition of 3H-thymidine and 35S-methionine in­
corporation in (respectively) newly synthesized DNA and pro­
teins by VT-1 of one representative population of human 
mesangial cells of three. Four hours of exposure to VT-1 at 
concentrations ranging from 10 pmol/L to 10 nmol/L was 
sufficient to reduce the DNA- and protein-synthesis rate. This 
inhibitory effect increased after 12 and 24 h of exposure, At all 
times and concentrations tested, 3H~thymidine incorporation 
was inhibited to a higher extent than was 35S-methionine. The 
inhibitory effects of VT-1 on DNA and protein synthesis were 
dependent on the degree of cell density and on the preexposure 
to TNFa (10 ng/ml) as depicted in Figure 6 . Four independent 
experiments with two different mesangial cell populations 
showed that subconfluent mesangial cells display the highest 
susceptibility. VT-1 susceptibility increased after preexposure 
to TNFa (Figure 6). Also, in this case, 3H-thymidine incorpo­
ration was inhibited to a higher extent than was 35S-methio- 
nine.
No major differences were observed when the effects of 
VT-1 and VT-2 were compared; both inhibited the overall 
synthesis of proteins, although VT-1 was slightly more potent 
than VT-2. After 24-h exposure to VT-1 and VT-2 (1 nmol/L), 
the mean overall protein synthesis in nonpretreated and TNFco­
pres timulated highly confluent mesangial cells of three differ­
ent populations of mesangial cells was, respectively, 72 ±  5 
and 50 ±  2% of control for VT-1-exposed cells and 89 ± 5 and 
72 ±  5% of control for VT-2-exposed cells (mean ±  SD). 
Exposure of TNF a-treated human mesangial cells to the B- 
subunit of the VT alone resulted in a significant inhibition of 
3H-thymidine incorporation, whereas 35S-methionine incorpo­
ration was not significantly affected. On a molecular base, the 
B-subunit alone inhibited DNA synthesis to a lesser extent than
did the holotoxin (Figure 7). To evaluate the possibility that 
protein synthesis inhibition by VT underlies the inhibition of 
^H-thymidine incorporation, we compared the effect of VT 
with that of the protein synthesis inhibitor cycloheximide 
(CHX). For proper comparison, we determined which CHX 
concentrations inhibited protein synthesis to a similar extent as 
did VT-2. On the basis that CHX (0.1 /xg/ml) and VT-2 (0.1 
nmol/L) inhibited protein synthesis 30 to 40%, only VT-2 
inhibited 3H-thymidine incorporation (Table 3). Correspond­
ingly, protein synthesis at a given proliferation rate was much 
more inhibited in cases of CHX treatment when compared with 
VT treatment (data not shown). This suggests that inhibition of 
DNA synthesis proceeds at least partly independently of pro­
tein synthesis inhibition.
Discussion
The leading cause of acute renal failure in children is the 
epidemic form of HUS, the etiology of which is associated 
with a VT-producing Escherichia coli. Although the role of 
endothelial cell damage in the pathogenesis in HUS is well 
described in the literature, the involvement of mesangial cells 
is scarcely documented (6,37). The interaction of VT with 
purified human mesangial cells was the subject of this in vitro 
study, We have described a modified technique for the culture 
of highly purified human mesangial cells free of contaminating 
endothelial and epithelial cells. We demonstrated that human 
mesangial cells bind VT to three molecular forms of neutral 
glycolipids identical or closely related to Gb3. One band was 
comparable to the VT receptor present in monocytes, in which 
it has previously been shown that VT induces cytokine release 
(33). The two other bands are most probably Gb3 species with 
different fatty acyl moieties (35,36). Similar Gb3 species are 
present in TNFa-treated endothelial cells (3,34), in which it 
has been shown that VT induces cytotoxicity. In mesangial 
cells, VT did not induce cytokine release. VT markedly inhib­
ited DNA and protein synthesis by two distinct mechanisms, 
but these effects were not associated with cell death.
The culture of human mesangial cells is, in several aspects, 
more difficult than that of rat mesangial cells. First, primary 
cultures of human mesangial cells are contaminated by epithe­
lial and small numbers of endothelial cells. In particular, the 
epithelial cells continue to grow, even when mesangial cells 
appear after 10 to 30 d of culture. On the contrary, the culture
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Figure 5„ VT-1 inhibits cell proliferation and overall protein synthesis 
in human mesangial cells in a time- and dose-dependent manner. 
Human mesangial cells of one representative donor (of three) were 
grown to confluence and subsequently incubated with either control 
medium (circle), VT-1 (10 nmol/L; triangle), VT-1 (1 nmol/L; 
square), VT-1 (0.1 nmol/L; diamond), or VT-1 (10 pmol/L; plus sign) 
in the presence of 3H-thymidine and 35S-methionine. After 24 h, the 
incorporation of 3H-thymidine and 35S-methionine into (respectively) 
newly synthesized DNA (A) and 35S-proteins (B) was determined 
according to the descriptions in Materials and Methods.
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Figure 6, The degree of cell density of cultured mesangial cells is 
related to inhibitory effects of VT-1 on cellular proliferation and 
overall protein synthesis. Human mesangial cells were grown to 
confluence, trypsinized, and split 1:5 onto gelatin-coated 24-well 
plates. Subconfluent (1), confluent (2), and highly confluent (3) mes­
angial cells were preexposed to either control medium (open bar) or 
TNFa: (10 ng/ml; hatched bar), respectively, for 24 h. Subsequently, 
the cells were washed and exposed to either control medium or 
medium supplemented with VT-1 (1 nmol/L) in the presence of 
3H-thymidine and 35S-methionine for 48 h, after which the incorpo­
ration of 3H-thymidine and 35S-methionine into (respectively) newly 
synthesized DNA (A) and 35S-proteins (B) was determined according 
to the descriptions in Materials and Methods. Data are expressed as 
percentages of control.
of rat mesangial cells is not hampered by contaminating epi­
thelial cells, because these epithelial cells do not survive during
the first weeks of culture. Secondly, no specific marker for Dynabeads coated with UEA-I, which recognizes L-a-fucose 
human mesangial cells is available for immunoselection (38), residues, appeared to be a valuable ligand for removal of all 
whereas the anti-Thy-1 antigen is a specific marker for rat epithelial cells from the mesangial cell culture. The avid bind- 
mesangial cells (38). Therefore, we have adapted the existing ing of epithelial cells to UEA-I corresponds with immuno­
procedure to enrich the mesangial cell populations (22) by chemical studies in v ivo, which show that UEA-I binds to cell 
additional selective removal of the contaminating epithelial membranes of epithelial and endothelial cells in the kidney 
cells. An immunomagnetic separation technique that uses (39-43). Indeed, the resulting cell populations of human mes-
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the majority of highly confluent cultures of mesangial cells, 
whereas highly confluent cultures of fibroblasts do not express 
this antigen.
Previous studies have demonstrated that VT-1 affects endo­
thelial cells (3,34) and monocytes (33,44) by different mech­
anisms. However, its effect on mesangial cells in vitro is poorly 
investigated. Only recently, Robinson et al. (37) reported on 
the binding of FITC-labeled VT-1 B-subunit to mesangial cells 
in vitro and the subsequent dose-dependent inhibitory effect of 
VT on mitogenesis of mesangial cells of one donor. Our report 
extends these observations and demonstrates that mesangial 
cells are not particularly susceptible to the cytotoxic effect of 
VT; however, they do bind VT to their cell membrane via 
1 6  different types of glycolipid receptors. One of these receptors
is comparable to that on monocytes, in which it induces cyto­
kine release. From a pathogenetic point of view, these inflam­
matory mediators play an important role in sensitizing glomer­
ular microvascular endothelial cells to the cytotoxic effect of 
VT by induction of the Gb3 receptor on the cell surface (34). 
Besides, inflammatory mediators render the endothelium pro­
coagulant and proinflammatory; these processes possibly con­
tribute to the pathological findings observed in HUS patients, 
Chemokines may be involved in the pathogenesis of HUS by 
the recruitment of leukocytes into the kidney. In vivo data 
support the involvement of inflammatory mediators and che­
mokines in the pathogenesis of HUS, demonstrating elevated 
levels in urine and, to a lesser extent, in the plasma of HUS 
patients (45-48). In addition to monocytes, human mesangial 
cells have been reported to act as a source of inflammatory 
mediators and chemokines. The data presented here indicate 
that VT-1 does not induce the production of various cytokines 
or chemokines by human mesangial cells. As previously de­
scribed, we have shown that LPS, which may play a role in the 
pathogenesis of HUS (33), induces human mesangial cells to 
produce and release cytokines and chemokines.
The cytotoxic effect of VT has originally been demonstrated 
to occur via inhibition of the elongation factor-1-dependent 
binding of aminoacyl-tRNA to the ribosomes by the A-subunit 
of VT (17,18), resulting in inhibition of eukaryotic protein 
synthesis, although an induction of apoptosis has also been 
observed (49-51). For the inhibitory effect on protein synthe­
sis, the A-subunit has to be internalized by the cell, which 
requires the binding of the B-subunits of VT to the cell surface 
via its glycolipid receptor Gb3 (19). We showed that this 
receptor is also present on human mesangial cells and is 
upregulated after exposure to TNFa, similar to its expression 
on endothelial cells (3,34). Although VT-1 interaction caused 
complete inhibition of protein synthesis and cell death in vero 
cells and TNFa-treated endothelial cells (3,34), it inhibited 
protein synthesis in mesangial cells by approximately 75% 
angial cells did not show immunoreactivity for PEC AM-1 or without a significant effect on cell viability, either under basal 
cytokeratin 8, excluding endothelial and epithelial cell contain- conditions or after upregulation of the Gb3 moieties by TNFa. 
ination, respectively. It seems unlikely that fibroblasts are Apparently, the residual 25% of protein synthesis is sufficient 
present among mesangial cell cultures because mesangial cells for mesangial cells to survive. However, in conditions of 
were isolated from primary outgrowths of pure populations of increased demand of protein synthesis, the reduced capacity to 
glomeruli. This suggestion is strengthened by the observation synthesize new proteins may affect cell function.
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Figure 7. This figure shows the inhibitory effects of VT-1 and the 
B-subunit alone on cell proliferation and overall protein synthesis. 
Confluent layers of mesangial cells of one representative donor were 
trypsinized and seeded 1:5 onto gelatin-coated wells. After 3,4, 8, and 
11 d, the mesangial cells (representing cells with different cell den­
sities) were pretreated with TNFa (10 ng/ml) for 24 h. A, Subcon­
fluent mesangial cells; B, confluent mesangial cells; C, highly con­
fluent mesangial cells. The cells were subsequently washed once and 
exposed to either control medium (circles), VT-1 (1 nmol/L; triangles; 
equivalent to 5 nmol/L B-subunit), or the B-subunit alone (1 jug/ml; 
squares; equivalent to 132 nmol/L B-subunit) in the presence of 
3H-thymidine and 35S-methionine for 48 h, after which the incorpo­
ration of 3H-thymidine and 35S-methionine into (respectively) newly 
synthesized DNA (Panel A) and 35S-proteins (Panel B) was deter­
mined according to the descriptions in Materials and Methods.
that immunoreactivity for a-smooth muscle actin is present in In addition to reducing protein synthesis, VT-1 also inhib-
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Table 3. Effect of the protein synthesis inhibitors VT and cycloheximide on cell proliferation and overall protein synthesis*1
Donor
VT-2 (0.1 nmol/L) CHX (0.1 jug/ml)
35S-Proteins :lH-Thymidine Incorporation 35S-Proteins 3H-Thymidine Incorporation
Donor 1 
Donor 2
61.0% of C 
69.9% of C
44.3% of C 
49.8% of C
61.5% of C 
62.9% of C
113% of C 
118% of C
a CHX, cycloheximide; C, control.
ited cell proliferation in human mesangial cells. One may inducing effects of VT oil mesangial cells play a minor role in
anticipate that this is caused by the reduced protein synthesis the development of renal failure in HUS. However, the facil-
rate, However, the inhibitory effect of VT-1 on proliferation itated access of damaging plasma constituents, procoagulatory
was larger and faster than that on protein synthesis. Further- agents, infiltrating leukocytes, and their products may put a
more, the B-subunit, which did not significantly inhibit protein demand on mesangial cells to which they cannot adequately
synthesis, also caused a dose- and time-dependent inhibition of respond because of a reduced capacity to synthesize new
cell proliferation. This points to an additional inhibitory effect proteins. In addition, the pathological findings in the mesangial
of VT on cell proliferation, independent of the reduction of area observed in some of the biopsies of HUS patients may be
protein synthesis. This suggestion is strengthened by our ob- initiated by the effects of VT-1 on mesangial cells described in
servation that partial inhibition of protein synthesis by VT-1 this report.
was associated with a considerably higher inhibition of cell
proliferation than a comparable inhibition of protein synthesis Acknowledgments 
by cycloheximide, which is known to block the peptidyl trans­
ferase reaction on the ribosomes. The observations that the 
B-subunit of VT can induce apoptosis in Burkitt lymphoma 
cells (50) and affects cell proliferation of mesangial cells (this 
study) suggests that the B-subunit can, probably via interaction 
with Gb3, directly activate a signal transduction pathway.
The inhibitory effects on both overall protein synthesis and R eferen ces  
cell proliferation were dependent on the pretreatment with 
TNFa and the cell density. Several papers have reported that 
inflammatory mediators may sensitize cells (3,34) to the toxic 
effect of VT by an upregulation of the number of specific 
binding sites for VT. We extend this observation to mesangial 
cells, showing the constitutive expression of VT receptors with 
an increase in the number of VT receptors after TNFa pre­
treatment. The higher susceptibility of subconfluent cells when 
compared with confluent cells has also been described previ­
ously in the literature (3,52,53) and is in agreement with our
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findings. Most likely this higher susceptibility is related to the 
cell cycle-dependent exposure of Gb3 compounded with in­
creased Gb3 turnover (53).
We conclude from this study with highly purified human 
mesangial cells that these cells bind VT-1 to specific glycolipid 
receptors but are not susceptible to the VT cytotoxicity. VT did 
not induce the release of cytokines but did inhibit DNA 
and—to a lesser extent— overall protein synthesis in mesangial 
cells. Two distinct mechanisms appeared to be involved in 
these inhibitory effects. One involves the effect of the A- 
subunit on overall protein synthesis. The second mechanism 
involves a B-subunit-linked inhibition of mitogenesis. The 
intracellular routing of VT (A- and B-subunits) toward the 
lysosomes, endos omes, Golgi and endoplasmic reticulum, or 
the nuclear membrane may vary between different cell types, 
possibly in relation to the fatty-acyl chain lengths of the gly­
colipid VT receptors (54-57).
The data presented here suggest that toxic and cytokine-
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